Sodium zirconium cyclosilicate for MRAs optimization in HFrEF: lessons learned from the REALIZE-K trial

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Mineralocorticoid receptor antagonists (MRAs) are crucial for heart failure with reduced ejection fraction (HFrEF) but risk hyperkalemia, especially in chronic kidney disease.
• Hyperkalemia often limits MRA use, leading to suboptimal treatment and poorer patient outcomes.
• Novel potassium binders, patiromer and sodium zirconium cyclosilicate (SZC), offer solutions for managing hyperkalemia.

Purpose of the Study:

• To review the REALIZE-K trial findings on SZC in HFrEF patients on spironolactone.
• To contextualize potassium binders within current evidence for optimizing MRA therapy.
• To explore barriers to MRA optimization and strategies to overcome them.

Main Methods:

• Critical examination of the REALIZE-K randomized withdrawal trial.
• Review of existing literature on potassium binders and MRA therapy.
• Analysis of clinical inertia and psychological barriers to MRA use.

Main Results:

• SZC effectively managed hyperkalemia in HFrEF patients receiving spironolactone.
• Potassium binders facilitate MRA dose optimization, improving guideline-directed therapy.
• Clinician concerns regarding hyperkalemia contribute significantly to treatment inertia.

Conclusions:

• Potassium binders like SZC are valuable tools for enabling MRA therapy in HFrEF.
• Addressing both physiological (hyperkalemia) and psychological (clinician concerns) barriers is key to enhancing MRA utilization.
• Optimizing MRA therapy has the potential to improve clinical outcomes in HFrEF patients.